vs
Side-by-side financial comparison of FIRST HORIZON CORP (FHN) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
FIRST HORIZON CORP is the larger business by last-quarter revenue ($888.0M vs $708.5M, roughly 1.3× Medpace Holdings, Inc.). FIRST HORIZON CORP runs the higher net margin — 29.4% vs 19.1%, a 10.3% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 21.8%). FIRST HORIZON CORP produced more free cash flow last quarter ($389.0M vs $188.1M). Over the past eight quarters, FIRST HORIZON CORP's revenue compounded faster (20.0% CAGR vs 17.7%).
First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
FHN vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $888.0M | $708.5M |
| Net Profit | $261.0M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 38.5% | 21.6% |
| Net Margin | 29.4% | 19.1% |
| Revenue YoY | 21.8% | 32.0% |
| Net Profit YoY | 57.2% | 15.5% |
| EPS (diluted) | $0.51 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $888.0M | $708.5M | ||
| Q3 25 | $889.0M | $659.9M | ||
| Q2 25 | $830.0M | $603.3M | ||
| Q1 25 | $812.0M | $558.6M | ||
| Q4 24 | $729.0M | $536.6M | ||
| Q3 24 | $827.0M | $533.3M | ||
| Q2 24 | — | $528.1M | ||
| Q1 24 | $819.0M | $511.0M |
| Q4 25 | $261.0M | $135.1M | ||
| Q3 25 | $262.0M | $111.1M | ||
| Q2 25 | $241.0M | $90.3M | ||
| Q1 25 | $218.0M | $114.6M | ||
| Q4 24 | $166.0M | $117.0M | ||
| Q3 24 | $218.0M | $96.4M | ||
| Q2 24 | — | $88.4M | ||
| Q1 24 | $192.0M | $102.6M |
| Q4 25 | 38.5% | 21.6% | ||
| Q3 25 | 38.7% | 21.5% | ||
| Q2 25 | 37.2% | 20.9% | ||
| Q1 25 | 35.1% | 20.3% | ||
| Q4 24 | 28.8% | 23.4% | ||
| Q3 24 | 34.0% | 21.1% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | 31.0% | 20.4% |
| Q4 25 | 29.4% | 19.1% | ||
| Q3 25 | 29.5% | 16.8% | ||
| Q2 25 | 29.0% | 15.0% | ||
| Q1 25 | 26.8% | 20.5% | ||
| Q4 24 | 22.8% | 21.8% | ||
| Q3 24 | 26.4% | 18.1% | ||
| Q2 24 | — | 16.7% | ||
| Q1 24 | 23.4% | 20.1% |
| Q4 25 | $0.51 | $4.65 | ||
| Q3 25 | $0.50 | $3.86 | ||
| Q2 25 | $0.45 | $3.10 | ||
| Q1 25 | $0.41 | $3.67 | ||
| Q4 24 | $0.29 | $3.67 | ||
| Q3 24 | $0.40 | $3.01 | ||
| Q2 24 | — | $2.75 | ||
| Q1 24 | $0.33 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.8B | $459.1M |
| Total Assets | $83.9B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | — | $669.4M | ||
| Q3 24 | — | $656.9M | ||
| Q2 24 | — | $510.9M | ||
| Q1 24 | — | $407.0M |
| Q4 25 | $8.8B | $459.1M | ||
| Q3 25 | $8.9B | $293.6M | ||
| Q2 25 | $9.0B | $172.4M | ||
| Q1 25 | $8.7B | $593.6M | ||
| Q4 24 | $8.8B | $825.5M | ||
| Q3 24 | $9.0B | $881.4M | ||
| Q2 24 | — | $763.6M | ||
| Q1 24 | $8.9B | $671.5M |
| Q4 25 | $83.9B | $2.0B | ||
| Q3 25 | $83.2B | $1.8B | ||
| Q2 25 | $82.1B | $1.6B | ||
| Q1 25 | $81.5B | $1.9B | ||
| Q4 24 | $82.2B | $2.1B | ||
| Q3 24 | $82.6B | $2.1B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | $81.8B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $396.0M | $192.7M |
| Free Cash FlowOCF − Capex | $389.0M | $188.1M |
| FCF MarginFCF / Revenue | 43.8% | 26.6% |
| Capex IntensityCapex / Revenue | 0.8% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.52× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $595.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $396.0M | $192.7M | ||
| Q3 25 | $-200.0M | $246.2M | ||
| Q2 25 | $83.0M | $148.5M | ||
| Q1 25 | $349.0M | $125.8M | ||
| Q4 24 | $191.0M | $190.7M | ||
| Q3 24 | $389.0M | $149.1M | ||
| Q2 24 | — | $116.4M | ||
| Q1 24 | $838.0M | $152.7M |
| Q4 25 | $389.0M | $188.1M | ||
| Q3 25 | $-208.0M | $235.5M | ||
| Q2 25 | $74.0M | $142.4M | ||
| Q1 25 | $340.0M | $115.8M | ||
| Q4 24 | $174.0M | $183.0M | ||
| Q3 24 | $383.0M | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | $828.0M | $147.2M |
| Q4 25 | 43.8% | 26.6% | ||
| Q3 25 | -23.4% | 35.7% | ||
| Q2 25 | 8.9% | 23.6% | ||
| Q1 25 | 41.9% | 20.7% | ||
| Q4 24 | 23.9% | 34.1% | ||
| Q3 24 | 46.3% | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | 101.1% | 28.8% |
| Q4 25 | 0.8% | 0.6% | ||
| Q3 25 | 0.9% | 1.6% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 1.1% | 1.8% | ||
| Q4 24 | 2.3% | 1.4% | ||
| Q3 24 | 0.7% | 2.0% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | 1.2% | 1.1% |
| Q4 25 | 1.52× | 1.43× | ||
| Q3 25 | -0.76× | 2.22× | ||
| Q2 25 | 0.34× | 1.65× | ||
| Q1 25 | 1.60× | 1.10× | ||
| Q4 24 | 1.15× | 1.63× | ||
| Q3 24 | 1.78× | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | 4.36× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHN
| Commercial Consumer And Wealth Segment | $776.0M | 87% |
| Other | $88.0M | 10% |
| Corporate | $24.0M | 3% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
